The paper proposes how to determine an effective radiation dose for patients undergone X-ray examinations, which includes the estimation of the size of a field while measuring the superficial dose and the assessment of an experiment protocol by taking into account the X-ray receiver used to measure exposure.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Utilization of MANAGE-PD Tool in a Real-World Setting in Germany: A Cross-Sectional Study.
Brain Sci
June 2024
Parkinson-Klinik Ortenau, 77709 Wolfach, Germany.
Article Synopsis
- MANAGE-PD is a web-based tool designed to help doctors identify Parkinson's disease patients whose symptoms aren't well managed by oral medications, with a modified version available in Germany called Parkinson Check.
- A study conducted in Germany in 2022 assessed the real-world utility of both tools using patient and physician ratings of disease control, involving 278 patients from 19 different sites.
- The results showed that 57.6% of patients received the same disease control assessment from both physicians and MANAGE-PD, with higher agreement in specialist clinics compared to neurologist practices, and the Parkinson Check demonstrated strong concordance (>80%) between physician and patient responses.
Grasping the big picture: impact analysis of screening tools for timely referral for device-aided therapies.
J Neural Transm (Vienna)
November 2024
Department of Neurology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Several screening tools are available to assist general neurologists in the timely identification of patients with advanced Parkinson's disease (PD) who may be eligible for referral for a device-aided therapy (DAT). However, it should be noted that not all of these clinical decision rules have been developed and validated in a thorough and consistent manner. Furthermore, only a limited number of head-to-head comparisons have been performed.
View Article and Find Full Text PDFLevodopa-based device-aided therapies for the treatment of advanced Parkinson's disease: a social return on investment analysis.
Front Public Health
July 2024
HTANALYSTS Pty Ltd., Sydney, NSW, Australia.
Introduction: Parkinson's disease (PD) is an incurable, progressive, neurodegenerative disorder. As PD advances and symptoms progress, patients become increasingly dependent on family and carers. Traditional cost-effectiveness analyses (CEA) only consider patient and payer-related outcomes, failing to acknowledge impacts on families, carers, and broader society.
View Article and Find Full Text PDFAre 5-2-1 Delphi criteria and MANAGE-PD useful screening tools for general neurologists for qualification to device-aided therapies in advanced Parkinson's Disease?
Neurol Neurochir Pol
August 2024
University Clinical Centre of K. Gibiński, Katowice, Poland.
Aim Of Study: We sought to compare MANAGE-PD and 5-2-1 Delphi criteria which are two commonly used and approved screening tools in Parkinson's Disease, in order to highlight their strengths and limitations.
Clinical Rationale For Study: Timely intervention with device-aided therapies is vital as it enables improving motor symptoms, lowering the dosage and side-effects of dopaminergic treatment, and improving patients' and caregivers' quality of life. Various screening tools have been created to help clinicians find the best candidates for device-aided therapies (DAT) for advanced Parkinson's Disease.
What was first and what is next in selecting device-aided therapy in Parkinson's disease? Balancing evidence and experience.
J Neural Transm (Vienna)
November 2024
Chulalongkorn Centre of Excellence for Parkinson's Disease and Related Disorders, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Parkinson's disease (PD) progresses with motor fluctuations emerging several years after treatment initiation. Initially managed with oral medications, these fluctuations may later necessitate device-aided therapy (DATs). Globally, various DATs options are available, including continuous subcutaneous apomorphine infusion, deep brain stimulation, levodopa-carbidopa intestinal gel, levodopa-entacapone-carbidopa intestinal gel, and subcutaneous foslevodopa/foscarbidopa infusion, each with its complexities.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!